<p>Steroidna jedinjenja spadaju u grupu supstanci sa &scaron;irokim spektrom biolo&scaron;kog delovanja i predstavljaju dobru polaznu osnovu za sintezu mnogih derivata sa željenim biolo&scaron;kim potencijalom. Organskim sintezama se do&scaron;lo do velikog broja steroidnih derivata, od kojih su neki pokazali značajnu biolo&scaron;ku aktivnost, kao &scaron;to je citotoksičnost prema različitim ćelijskim linijama kancera. Karakterizacija novosintetisanih jedinjenja može se izvesti eksperimentalnim i računarskim (in silico) metodama. U ovoj doktorskoj disertaciji predstavljeno je eksperimentalno određivanje lipofilnosti 17&alpha;-pikolil i 17(E)-pikoliniliden androstanskih derivata primenom visokopritisne tečne hromatografije na obrnutim fazama, a potom hemometrijska analiza hromatografskog pona&scaron;anja (hromatografske lipofilnosti) QSRR pristupom. Hemijska struktura analiziranih derivata opisana je numerički, pomoću izračunatih molekulskih deskriptora. U drugom delu doktorske disertacija predstavljena je QSAR analiza citotoksične aktivnosti 17&alpha;-pikolil i 17(E)-pikoliniliden androstanskih derivata prema ćelijama androgen-receptor negativnog kancera prostate (AR-neg. PC-3). Odabir najkvalitetnijih QSRR i QSAR modela obavljen je na osnovu izračunatih statističkih parametara, a njihovo rangiranje izvedeno je primenom metode sume razlika rangova (SRD). Pored regresionih QSRR i QSAR hemometrijskih metoda, primenjene su i klaster analiza i analiza glavnih komponenata sa ciljem utvrđivanja sličnosti ili razlika između analiziranih derivata na<br />osnovu izračunatih molekulskih deskriptora.</p> / <p>Steroidal compounds belong to the group of substances with wide spectrum of biological activity and represent the basic material for synthesis of many derivatives<br />with preferred biological potential. A grate number of steroidal derivatives have been<br />obtained through organic syntheses, many of which have demonstrated significant<br />biological activity, such as cytotoxicity toward various cancer cell lines. Characterization of newly synthesized compounds can be achieved experimentally<br />and by computational approach (in silico). This doctoral dissertation describes<br />experimental determination of lipophilicity of 17&alpha;-picolyl and 17(E)-picolinylidene<br />androstane derivatives applying reversed-phase high pressure liquid chromatography followed by quantitative structure-retention relationship (QSRR)<br />chemometric analysis of chromatographic behaviour (chromatographic lipophilicity).<br />Chemical structure of the analyzed derivatives was described numerically by in silico<br />molecular descriptors. The second part of this dissertation describes quantitative<br />structure-activity relationship (QSAR) analysis of cytotoxic activity of 17&alpha;-picolyl and<br />17(E)-picolinylidene androstane derivatives toward androgen-receptor negative<br />prostate cancer cell line (AR-neg. PC-3). Selection of the best QSRR and QSAR<br />models was carried out based on their statistical parameters, and their ranking was<br />done by sum of ranking differences (SRD) method. Besides the regression QSRR and QSAR chemometric methods, cluster analysis and principal components analysis were conducted in order to reveal possible similarities and dissimilarities among the studied derivatives on the basis of calculated molecular descriptors.</p>

No description available.

Targeting the anticancer agents selectively to cancer cells is desirable to improve the efficacy and to reduce the side effects of anticancer therapy. Previously reported passive tumor targeting by PEGylated liposomes (stealth liposomes) have resulted in their higher tumor accumulation. However their interaction with cancer cells has been minimal due to the steric hindrance of the PEG coating. This dissertation reports two approaches to enhance the interaction of stealth liposomes with cancer cells. First, we designed a lipid-hydrazone-PEG conjugate that removes the PEG coating at acidic pH as in the tumor interstitium. However, such a conjugate was highly unstable on shelf. Targeting the anticancer agents selectively to cancer cells is desirable to improve the efficacy and to reduce the side effects of anticancer therapy. Previously reported passive tumor targeting by PEGylated liposomes (stealth liposomes) have resulted in their higher tumor accumulation. However their interaction with cancer cells has been minimal due to the steric hindrance of the PEG coating. This dissertation reports two approaches to enhance the interaction of stealth liposomes with cancer cells. First, we designed a lipid-hydrazone-PEG conjugate that removes the PEG coating at acidic pH as in the tumor interstitium. However, such a conjugate was highly unstable on shelf. Second we developed lipids with imidazole headgroups. Such lipids can protonate to provide positive charges on liposome surface at lowered pH. Additionally, negatively charged PEGylated phospholipids can cluster with the protonated imidazole lipids to display excess positive charges on the surface of the liposomes, thus enhancing their interaction with negatively charged cancer cells. We prepared convertible liposome formulations I, II and III consisting of one of the three imidazole-based lipids DHI, DHMI and DHDMI with estimated pKa values of 5.53, 6.2 and 6.75, respectively. Zeta potential measurement confirmed the increase of positive surface charge of such liposomes at lowered pHs. DSC studies showed that at pH 6.0 formulation I formed two lipid phases, whereas the control liposome IV remained a one-phase system at pHs 7.4 and 6.0. The interaction of such convertible liposomes with negatively charged model liposomes mimicking biomembranes at lowered pH was substantiated by 3-4 times increase in average sizes of the mixture of the convertible liposomes and the model liposomes at pH 6.0 compared to pH 7.4. The doxorubicin-loaded convertible liposomes show increased cytotoxicity in B16F10 (murine melanoma) and Hela cells at pH 6.0 as compared to pH 7.4. Liposome III shows the highest cell kill at pH 6.0 for both the cells. The control formulation IV showed no difference in cytotoxicity at pH 7.4 and 6.0. Uptake of convertible liposome II by B16F10 cells increased by 57 % as the pH was lowered from 7.4 to 6.0.

The current dissertation describes a multidisciplinary research project centered on the discovery and investigation of the anticancer activities exhibited by novel piperazinylpyrimidine derivatives designed to target kinases protein family. Primary screening of the antiproliferative effects implemented by these successfully synthesized new agents has resulted in the candidacy of 4 , 15 , and 16 as not only prototype representatives of the class, but surprisingly also as optimized agents for either globally cytotoxic, 16 , or selectively cytostatic, 4 and 15 , agents. Subjecting 4 , 15 , and 16 to screening tests aiming at measuring their binding to or their functional inhibition of selected sets of kinases has revealed the tendency of 4 to target PDGFR subfamily and the ability of 4 , 15 , and 16 to recognize CSNK1D. Docking as well as binding profiles comparative studies hypothesize 4 , 15 , and 16 as type-I kinase inhibitors. Further preclinical investigation of 15 against MDA-MB-468 triple negative breast cancer cell line revealed that 15 exhibits a time as well as dose-dependent antiproliferative activity mediated by the induction of both time and dose independent G2/M arrest and dose dependent apoptosis. Globally studying the molecular events accompanied with the 15 /MDA-MB-468 incidence has revealed the phosphorylation of TP53 and the consequent activation of its transcriptional activity as a hallmark molecular event relevant to the above observed effects on the cellular, cell cycle, and programmed cell death levels. Apart from the above experimentally oriented investigation, another theoretically driven inquiry was pursued aiming at studying the inherent ability of certain kinases to be more promiscuous towards binding to small molecules than others. Throughout the analysis of a reported dataset, dephosphorylated members of PDGFR subfamily were found to more potently bind to structurally diverse kinase inhibitors compared to INSR subfamily. A molecular dynamics study was performed to compare between the topological, energetic, and dynamic properties of the binding area usually targeted by kinase inhibitors in both KIT, as a representative of the more promiscuous PDGFR subfamily, and INSR, as a representative of the less promiscuous INSR subfamily. Interestingly enough, the binding area in both kinases showed significantly different properties which, to a large extent, can explain their different overall attitudes towards binding small molecules. As a representative example, the binding area of INSR tends to be more energetically self-stabilizing than that in KIT. Additionally, the topological analysis revealed that the binding are in KIT tends to be more rigid and to have bigger size than that of INSR. The current work has successfully cross-implemented experimental, theoretical, and computational studies aiming at the development of novel kinase inhibitors and/or promising anticancer preclinical candidates.

Cancer is a leading cause of mortality worldwide, responsible for nearly one in six deaths. Thus, there is a need for a greater understanding of cancer for the development of novel therapeutics. This master thesis project aims to compare the proteome signatures between dying and surviving cancer cells treated with diverse anticancer drugs. The first aim is to investigate if drug targets behave similarly and have the same sign (up- or down-regulation) in dying versus surviving cells. The second aim is to validate that combining the dying cancer cell’s proteome with the surviving cell’s can help improve drug target rankings for anticancer treatments. The third aim is to identify proteins and pathways involved in life and death decisions by comparing dying and surviving states in response to the anticancer drugs in different cell lines. First, we demonstrate that drug target behaviour in dying versus surviving cells is almost identical for nine diverse anticancer compounds with a correlation of 0.93. To identify drug targets, orthogonal partial least squares-discriminant analysis (OPLS-DA) modelling was performed to contrast the proteome signature of one anticancer drug against all other drugs and rank the proteins based on the magnitude of the model’s predictive component. There were occasions when the dying cells gave better rankings than the surviving ones. In some cases, the best target rankings were obtained when combining the data from both surviving and dying cells. To identify proteins and pathways involved in life and death decisions, OPLS-DA modelling contrasting the two states was performed, and heatmaps and scatterplots of dying and surviving log2 fold changes were made. As a result, several pathways involved in cell survival and cell death were identified. In addition, at least six proteins consistently differentially regulated between the surviving and dying cells were identified. Such proteins can be considered as putative survival (resistance) or sensitivity biomarkers and serve as potential drug targets for the development of novel anticancer agents.

Utveckling av polymer baserade läkemedelsbärare i nanostorlek har blivit allt viktigare för att effektivisera behandling och diagnosering av olika sjukdomar, speciellt cancer. Flera läkemedel som används i kemoterapi har bristfälliga egenskaper som låg löslighet i vatten, oönskad nedbrytbara till dess inaktiva form, och distribution i stora volymer till oönskade organ p.g.a. dess icke-selektiva förmåga. Nanopartiklar är små partiklar med diameter 1-500 nm som genom passiv/aktiv transport kan passera olika biologiska barriärer och transportera läkemedel i optimala mängder till specifika celler. Denna selektiva transport bidrar till ökad terapeutiskt index och minskning av toxiska effekter i övriga delar av kroppen. Hyperförgrenade linjär-dendritiska hybrider är en subgrupp av dendritiska polymer som har stor potential att användas som byggstenar i utvecklingen av läkemedelsbärare. I detta projekt producerades ett bibliotek av hyperförgrenade linjär-dendritiska material via Fischer esterifikation reaktionen som är en snabb, billig och uppskalningsbar produktionsmetod. Vidare post funktionaliserades materialen med allyl grupper för produktion av nano geler genom UV-inducerad korslänkning och vidare funktionalisering. Samtliga producerade hyperförgrenade linjär-dendritiska material hade förmågan att bilda miceller i vatten. Materialen med bäst micelle bildningsförmåga användes för att kemiskt korslänka dem och producera nano geler. Nano gelernas inre del funktionaliserades framgångsrikt med tre olika funktionella grupper; katjoniska, anjoniska och hydrofoba via resterande fria allyler. Detta påvisar att dessa dendritiska nano geler har potential att bära olika material som hydrofobiska läkemedel eller genetiskt material. Dom producerade nano gelerna hade en hydrodynamisk volym inom intervallet 124-200 nm. Detta är fördelaktigt då dem kan transporteras till tumörområdet via ökad permeabilitet och retention, också kallad EPR effekten, utan att initiera ett immunologiskt svar eller filtreras från blodomloppet via njuren. / The development of nano- based drug carriers is of high importance in anti-cancer treatment as anticancer drugs suffers from limitations as low aqueous solubility, non-selective targeting, off-target degradation and low therapeutic concentrations at target site. Hyperbranched polymers are potential candidates as drug carrier due to its unique properties as globular shape, high number of functional groups and high degree of branching. In addition, hyperbranched polymers are synthesized via one-step polymerization reaction with high yields, low costs and good scale-up possibilities. In this project a library of hyperbranched linear-dendritic hybrid materials based of 2,2-bis(hydroxymethyl)propionic acid (bis-MPA) and monofunctional poly (ethylene glycol) (mPEG) was synthesized via the Fischer esterification reaction. The materials were then post functionalised with hydrophobic allyl groups. The materials self-assembled into micelles in water and candidates with best self-assembly ability were used to fabricate dendritic nanogels by UV-induced cross-linking. The formed dendritic nanogels obtained a hydrodynamic volume between 124-200 nm, which indicates that these dendritic nanogels can be used as drug carrier and accumulate at target-site via the enhanced permeability and retention (EPR) effect. The dendritic nanogels inner core was also successfully attached with cationic, hydrophobic and anionic groups respectively. This confirmed that the dendritic nanogels have the potential to encapsulate different types of cargo such as DNA or hydrophobic drugs in the inner core.

[pt] Na busca de novos quimioterápicos diferentes dos clássicos derivados de cisplatina, ligantes derivados aroíl-hidrazônicos e complexos de cobre(II) aparecem como compostos promissores. Esta tese relata o desenvolvimento e a síntese de uma nova combinação desses compostos a partir de oito ligantes bases de Schift aroíl-hidrazônicos inéditos e seus Cu2-complexos derivados de sais de perclorato ou acetato 1‒14. Os complexos de cobre(II) obtidos contêm em suas estruturas modelos estruturais de sítios ativos de algumas metaloenzimas. Os compostos foram amplamente caracterizados utilizando várias técnicas espectroscópicas e analíticas. As análises por difração de raios X de quatro ligantes e cinco complexos são descritas em detalhes nessa tese. A estabilidade dos compostos foi estudada em meio celular e sua atividade biológica foi analisada. Os resultados incluem um estudo da interação de dois ligantes derivados de tiofeno (H3L1) ou furano (H3L2) e seus respectivos complexos 1 e 2 (primeiro conjunto de compostos) com uma proteína e DNA do timo de vitelo (calf thymus DNA), com o objetivo de medir a afinidade de ligação à albumina sérica bovina e ao DNA usando as técnicas de absorção de UV/Visível e/ou fluorescência. Adicionalmente, foi visto através de técnicas de espalhamento de luz que a interação entre os compostos e a proteína é reversível. Uma importante contribuição do presente trabalho foi analisar a capacidade de clivagem do DNA plasmidial de dois complexos 1 e 2 usando a técnica de espalhamento de luz dinâmico. Neste trabalho são estudadas as alterações do raio hidrodinâmico do DNA plasmidial causada pelo corte nas hélices resultante da presença dos complexos. Ensaios de citotoxicidades em algumas células cancerígenas, revelaram a alta capacidade dos ligantes (H3L1 and H3L2) e dos complexos (1 e 2) de induzir a morte celular. Ademais, as muitas propriedades biológicas, incluindo a atividade anticancerígena do fragmento isoxazol, motivaram sua inclusão na estrutura dos ligantes H3L3 and H2L4 e complexos 3‒6 (segundo conjunto de compostos). A combinação dessas estruturas pode vir a ser promissora na procura de novos medicamentos contra o câncer. A interação dos derivados dos ligantes isoxazol-aroíl-hidrazônicos com o DNA foi diretamente estudada por espectroscopia na absorbância e fluorescência, usando as propriedades luminescentes apresentadas pelos ligantes. No caso dos complexos, o ensaio de deslocamento de brometo de etídio revelou uma afinidade importante através da intercalação nos ácidos nucleicos da sequência do DNA. Adicionalmente, este trabalho conseguiu demostrar que ligantes e complexos contendo um braço fenólico no lugar de um braço piridínico melhoram a citotoxicidade in vitro em células de câncer de mama epitelial humano, alcançando a faixa nanomolar. A capacidade de metalação e transmetalação dos ligantes binucleares H3L3 e H2L4 e seus complexos de cobre 3‒6 com Fe(II), Fe(III) e Zn(II) provenientes do meio biológico foi verificada como uma estratégia adicional para induzir a morte de células cancerígenas. Além disso, para estudar a interação dos compostos com o sistema biológico e/ou para demostrar a permeabilidade celular dos compostos, os ligantes (H3L5‒H3L7) e complexos (7‒12) foram funcionalizados com fluoróforos potentes como pireno (H3L5) (conjunto três de compostos), benzopiranotiofeno (H3L6) ou borodipirrometeno (H3L7) (conjunto quatro de compostos) associados aos fragmentos hidrazônicos. Estudos de microscopia de fluorescência do ligando H3L7 comprovaram sua presença dentro de células de câncer. Também, análises de co-localização para organelas mostraram a afinidade dos ligantes com a mitocôndria. Finalmente, motivada pelas propriedades biológicas da molécula isoniaziada e seu uso em tratamentos de quimioterapia, esta tese mostra de forma general a síntese, caracterização e citotoxicidade de um novo ligante isoniazídico (H2L8) e seus complexos de perclorato ou acetato de cobre(II) 13 e 14 (conjunto cinco de compostos) visando realizar um pedido de patente. / [en] On the search of new chemotherapeutic agents differing from the classic cisplatin family drugs, aroylhydrazonic derivatives and their copper(II) complexes appear as promising compounds. This thesis reports on the design and syntheses of a novel combination of them through eight new aroylhydrazones and their fourteen perchlorate and/or acetate Cu2-complexes 1‒14. The obtained bioinspired copper(II) complexes constitute structural models for the active sites of some type 3 copper enzymes. The compounds were fully characterized using various spectroscopic and analytical techniques. X-ray diffraction structures for four ligands and five complexes are described in detail. Compounds stability was studied in cellular medium and their biological activity was examined. The results include a large study on the interaction of two thiophene (H3L1) or furan (H3L2) ligand derivatives and their respective μ-hydroxo dicopper complexes 1 and 2 (first set of compounds) respectively, with bovine serum albumin protein and calf thymus DNA using different spectroscopic techniques, which include the binding affinity to BSA and DNA using UV/Visible and/or fluorescence techniques. Additionally, scattering techniques revealed that the interaction between the compounds and BSA induces reversible aggregation of the biomolecules. As an important contribution of the present work, the plasmid DNA cleavage ability of the complexes 1 and 2 was studied by Dynamic Light Scattering. The changes of hydrodynamic radius values of pBR322 plasmid DNA are correlated to the nick induced by the complexes in the helices. Cytotoxic assays on some cancer cells revealed the high ability of H3L1 and H3L2, and complexes 1 and 2 to induce cell death. On the other hand, the many biological properties, including anticancer activity, of the isoxazole molecule, motivated the inclusion of this moiety in two ligands H3L3 and H2L4 and four complexes 3‒6 (second set of compounds). Interaction of these isoxazole-aroylhydrazonic ligand derivatives with DNA was directly studied by absorbance and fluorescence spectroscopy, as a result of the fluorescence properties displayed by the ligands. In the case of the isoxazole-aroylhydrazonic complexes-DNA interaction, the ethidium bromide displacement assay revealed significant affinity by intercalation binding mode of the nucleic acid in the DNA sequence. Additionally, this work successfully demonstrated that ligands and complexes containing a phenol pendant arm instead of a pyridine one improve the in vitro cytotoxicity on human epithelial breast cancer cells, attaining nanomolar range. Metal chelation and transmetallation ability of binucleating ligands H3L3 and H2L4 and their copper complexes 3‒6 with Fe(II), Fe(III) and Zn(II) from the biological medium was verified as an additional cell death induction anticancer strategy. Moreover, to study the interaction of the compounds with the biological system and to demonstrate their cell permeability, ligands (H3L5‒H3L7) and complexes (7‒12) were functionalized in their hydrazone moieties with potent fluorophores, such pyrene (H3L5) (set three of compounds), benzopyranothiophene (H3L6), or boron-dipyrromethene (H3L7) derivatives (set four of compounds). Fluorescence microscopy studies proved the presence of ligand H3L7 inside cancer cells, proving its ability to pass through the cell membrane. Besides, co-localization analysis for organelles showed the affinity of this ligand for the mitochondria. Finally, motived by the wide spectrum of biological properties of the isoniazid molecule and its use in chemotherapy, this thesis reports the syntheses, characterization and cytotoxicity studies on cancer cells of a new isonicotinoyl hydrazone ligand (H2L8) and its perchlorate or acetate copper(II) complexes 13 and 14 (set five of compounds), which are involved in a patent request.

Plusieurs agents anticancéreux très puissants sont caractérisés par une solubilité aqueuse limitée et une toxicité systémique importante. Cette dernière serait liée d’une part à la solubilisation des agents anticancéreux à l’aide de surfactifs de bas poids moléculaire, connus pour leur toxicité intrinsèque, et d’autre part, par le manque de spécificité tissulaire des anticancéreux. Les vecteurs colloïdaux à base de polymères permettraient de résoudre certains défis liés à la formulation d’agents anticancéreux hydrophobes. D’abord, les polymères peuvent être sélectionnés afin de répondre à des critères précis de compatibilité, de dégradation et d’affinité pour le médicament à formuler. Ensuite, le fait d’encapsuler l’agent anticancéreux dans un vecteur peut améliorer son efficacité thérapeutique en favorisant son accumulation au niveau du tissu cible, i.e. la tumeur, et ainsi limiter sa distribution au niveau des tissus sains. Des travaux antérieurs menés au sein de notre laboratoire ont mené à la mise au point de micelles à base de poly(N-vinyl-pyrrolidone)-bloc-poly(D,L-lactide) (PVP-b-PDLLA) capables de solubiliser des agents anticancéreux faiblement hydrosolubles dont le PTX. Ce dernier est commercialisé sous le nom de Taxol® et formulé à l’aide du Crémophor EL (CrEL), un surfactif de bas poids moléculaire pouvant provoquer, entre autres, des réactions d’hypersensibilité sévères. Bien que les micelles de PVP-b-PDLLA chargées de PTX aient démontré une meilleure tolérance comparée au Taxol®, leur potentiel de ciblage tumoral et leur efficacité thérapeutique étaient similaires à la forme commerciale à doses égales. Ceci était possiblement dû au fait que les micelles étaient rapidement déstabilisées et ne pouvaient retenir leur cargo suite à leur administration intraveineuse. Nous avons donc décidé de poursuivre les travaux avec un autre type de vecteur, soit des nanoparticules, qui possèdent une stabilité intrinsèque supérieure aux micelles. L’objectif principal de cette thèse de doctorat était donc de mettre au point des nanoparticules polymères pour l’administration parentérale d’agents anticancéreux faiblement solubles dans l’eau. Les nanoparticules devaient permettre d’encapsuler des agents anticancéreux hydrophobes et de les libérer de manière contrôlée sur plusieurs jours. De plus, elles devaient démontrer un temps de circulation plasmatique prolongée afin de favoriser l’accumulation passive du médicament encapsulé au niveau de la tumeur. La première partie du travail visait à employer pour la première fois le copolymère amphiphile PVP-b-PDLLA comme émulsifiant dans la préparation de nanoparticules polymères. Ainsi, une méthode de fabrication des nanoparticules par émulsion huile-dans-eau a été appliquée afin de produire des nanoparticules à base de PDLLA de taille inférieure à 250 nm. Grâce aux propriétés lyoprotectrices de la couronne de PVP présente à la surface des nanoparticules, celles-ci pouvaient retrouver leur distribution de taille initiale après lyophilisation et redispersion en milieu aqueux. Deux anticancéreux hydrophobes, soit le PTX et l’étoposide (ETO), ont été encapsulés dans les nanoparticules et libérés de ces dernières de façon contrôlée sur plusieurs jours in vitro. Une procédure de « salting-out » a été appliquée afin d’améliorer le taux d’incorporation de l’ETO initialement faible étant donnée sa solubilité aqueuse légèrement supérieure à celle du PTX. Le second volet des travaux visait à comparer le PVP comme polymère de surface des nanoparticules au PEG, le polymère le plus fréquemment employé à cette fin en vectorisation. Par le biais d’études d’adsorption de protéines, de capture par les macrophages et de biodistribution chez le rat, nous avons établi une corrélation in vitro/in vivo démontrant que le PVP n’était pas un agent de surface aussi efficace que le PEG. Ainsi, malgré la présence du PVP à la surface des nanoparticules de PDLLA, ces dernières étaient rapidement éliminées de la circulation sanguine suite à leur capture par le système des phagocytes mononucléés. Par conséquent, dans le troisième volet de cette thèse, le PEG a été retenu comme agent de surface, tandis que différents polymères biodégradables de la famille des polyesters, certains synthétiques (PDLLA et copolymères d’acide lactique/acide glycolique), d’autres de source naturelle (poly(hydroxyalkanoates)(PHAs)), ont été investiguées comme matériaux formant le cœur des nanoparticules. Il en est ressorti que les propriétés physicochimiques des polyesters avaient un impact majeur sur l’efficacité d’encapsulation du PTX et son profil de libération des nanoparticules in vitro. Contrairement aux PHAs, les polymères synthétiques ont démontré des taux d’incorporation élevés ainsi qu’une libération contrôlée de leur cargo. Des études de pharmacocinétique et de biodistribution ont démontré que les nanoparticules de PDLLA dotées d’une couronne de PEG conféraient un temps de circulation plasmatique prolongé au PTX et favorisaient son accumulation tumorale. Les nanoparticules polymères représentent donc une alternative intéressante au Taxol®. / Many highly potent anticancer drugs are characterized by poor aqueous solubility and can impart significant systemic toxicity. This toxicity can be attributed in part to the solubilisation of these anticancer agents with low molecular weight surfactants that are known to cause serious biological side effects on their own. Moreover, following their intravenous (IV) injection, the anticancer agents distribute throughout the body, causing deleterious effects in healthy organs and tissues. Colloidal polymeric drug carriers have been investigated as a means to circumvent these drawbacks. First, polymeric materials can be tailored to meet specific requirements in terms of biocompatibility, biodegradability and affinity for the cargo molecule. Second, associating a drug to a carrier system can drastically alter its distribution throughout the body, enhancing its deposition at the target site, e.g. the tumour, while sparing healthy tissues, thus minimizing systemic toxicity. Previous work in our group has led to the design of block copolymer micelles based on poly(N-vinyl-pyrrolidone)-block-poly(D,L-lactide) (PVP-b-PDLLA) that were shown to solubilise hydrophobic anticancer agents such as paclitaxel (PTX). PTX is commercially available as Taxol®, a Cremophor EL (CrEL)-based formulation. CrEL is a low molecular weight surfactant that has been linked to severe side effects including life-threatening hypersensitivity reactions. Although PTX-loaded PVP-b-PDLLA micelles have demonstrated much improved tolerability compared to Taxol®, they did not increase PTX tumoral concentrations and exhibited anticancer efficacy similar to Taxol® at equivalent dosage. This was attributed to rapid destabilisation of the micelles and release of their cargo following IV administration. We chose to pursue our work with a colloidal drug carrier that exhibits greater stability compared to block copolymer micelles, i.e. polymeric nanoparticles. The main objective of this project was to develop polymeric nanoparticles for the parenteral delivery of hydrophobic anticancer drugs. The nanoparticles had to meet certain requirements such as be able to encapsulate hydrophobic anticancer drugs and release them in a controlled fashion over several days. Furthermore, the nanoparticles should confer prolonged plasma residence times to the encapsulated drug and favour its passive accumulation at its intended site of action, i.e. the tumour. The first part of this work focussed on applying PVP-b-PDLLA for the first time as polymeric emulsifier for the preparation of PDLLA nanoparticles with appropriate mean diameters (250 nm) using an oil-in-water emulsion method. Two hydrophobic anticancer drugs, PTX and etoposide (ETO), were successfully incorporated into the nanoparticles. A salting-out method was applied to enhance the loading efficiency of ETO, which was initially low given its slightly higher aqueous solubility compared to PTX. Both drugs were released in a controlled fashion from the PDLLA nanoparticles in vitro. Because of the lyoprotective effect of PVP, the polymer corona allowed for the particles to be easily redispersed in aqueous media following lyophilisation. The second part of the thesis aimed at evaluating whether the PVP coating could confer “stealth” properties to the PDLLA nanoparticles. Our study provided direct comparison between PVP and PEG, the most widely employed surface agent in drug delivery. In vitro protein adsorption and phagocytosis studies corroborated the in vivo findings, which showed that PVP-coated nanoparticles were rapidly cleared from circulation following their uptake by the mononuclear phagocyte system. Hence, our results indicated that PVP as coating materiel is not as efficient as PEG in conferring “stealth” properties to polymeric nanoparticles. Consequently, in the last section of this thesis, PEG was selected as coating agent while various biodegradable polymers were investigated as core-forming materials. Both synthetic (PDLLA and lactide/glycolide copolymers) and natural (polyhydroxyalkanoates (PHAs)) polyesters were tested. Our results demonstrated that the physicochemical properties of the polyesters significantly influenced the loading efficiency and release kinetics of PTX. While nanoparticles based on synthetic polyesters exhibited high encapsulation levels and controlled PTX release in vitro, PHA-based nanoparticles exhibited immediate unloading of their cargo. Pharmacokinetic and biodistribution studies in rodents revealed that encapsulating PTX in PEG-coated PDLLA-based nanoparticles led to enhanced plasma residence time and tumour deposition of the drug compared to Taxol®. Polymeric nanoparticles thus represent an appealing alternative to Taxol®.

A biodiversidade de plantas brasileiras é uma fonte muito rica de moléculas bioativas, dentro da proposta da busca por novas drogas antitumorais, avaliamos neste estudo o potencial antiproliferativo do composto 7-epi-clusianona. Foram utilizadas duas linhagens celulares derivadas de tumor de mama humana, Hs 578T e MCF-7, cultivadas em monocamada e como esferoides. O IC50 após 48 horas de tratamento das células é de 20 &mu;M para Hs 578T e 6 &mu;M para MCF-7. A análise do ciclo celular mostrou que o composto é capaz de reter as células em fase G1/G0 em ambas as linhagens em 2D, mas não em 3D. O composto é capaz de induzir as células a senescência celular, como mostrado pelo ensaio de detecção de &beta;-galactosidase. Esses dados indicam que o composto 7-epi-clusianona é uma molécula promissora, que demonstrou potencial antitumoral em células de tumor de mama. A cultura tridimensional se mostrou mais resistente ao tratamento com 7-epi-clusianona, portanto estudos mais abrangentes são necessários para melhor entendimento dos efeitos do composto sobre esse tipo de cultura. / Brazilian flora is considered one of the most diverse in the world and natural products are some of the important sources of new antitumoral compounds. The aim of this study was to evaluate the antiproliferative potential of 7-epi-clusianone. Two cell lines derived from human breast tumor were used, Hs 578T and MCF-7, cultured in monolayer and as spheroids. The IC50 after 48 hours of treatment is 20 &mu;M to Hs 578T cells and 6 &mu;M to MCF-7 cells. Cell cycle analysis showed induction of cell cycle arrest in G1/S phase in cells cultured in monolayers, but not in spheroids. The amount of cells in senescence after the treatment with 7-epi-clusianone is higher than the control group, as seen by the senescence &beta;-galactosidase staining assay. These data suggest that 7-epi-clusianone is a promising molecule against breast cancer cells. We show that 3D culture was more resistant to treatment than 2D culture, therefore more comprehensive studies are needed to better understand the effects of 7-epi-clusianone on this kind of culture.

Plusieurs agents anticancéreux très puissants sont caractérisés par une solubilité aqueuse limitée et une toxicité systémique importante. Cette dernière serait liée d’une part à la solubilisation des agents anticancéreux à l’aide de surfactifs de bas poids moléculaire, connus pour leur toxicité intrinsèque, et d’autre part, par le manque de spécificité tissulaire des anticancéreux. Les vecteurs colloïdaux à base de polymères permettraient de résoudre certains défis liés à la formulation d’agents anticancéreux hydrophobes. D’abord, les polymères peuvent être sélectionnés afin de répondre à des critères précis de compatibilité, de dégradation et d’affinité pour le médicament à formuler. Ensuite, le fait d’encapsuler l’agent anticancéreux dans un vecteur peut améliorer son efficacité thérapeutique en favorisant son accumulation au niveau du tissu cible, i.e. la tumeur, et ainsi limiter sa distribution au niveau des tissus sains. Des travaux antérieurs menés au sein de notre laboratoire ont mené à la mise au point de micelles à base de poly(N-vinyl-pyrrolidone)-bloc-poly(D,L-lactide) (PVP-b-PDLLA) capables de solubiliser des agents anticancéreux faiblement hydrosolubles dont le PTX. Ce dernier est commercialisé sous le nom de Taxol® et formulé à l’aide du Crémophor EL (CrEL), un surfactif de bas poids moléculaire pouvant provoquer, entre autres, des réactions d’hypersensibilité sévères. Bien que les micelles de PVP-b-PDLLA chargées de PTX aient démontré une meilleure tolérance comparée au Taxol®, leur potentiel de ciblage tumoral et leur efficacité thérapeutique étaient similaires à la forme commerciale à doses égales. Ceci était possiblement dû au fait que les micelles étaient rapidement déstabilisées et ne pouvaient retenir leur cargo suite à leur administration intraveineuse. Nous avons donc décidé de poursuivre les travaux avec un autre type de vecteur, soit des nanoparticules, qui possèdent une stabilité intrinsèque supérieure aux micelles. L’objectif principal de cette thèse de doctorat était donc de mettre au point des nanoparticules polymères pour l’administration parentérale d’agents anticancéreux faiblement solubles dans l’eau. Les nanoparticules devaient permettre d’encapsuler des agents anticancéreux hydrophobes et de les libérer de manière contrôlée sur plusieurs jours. De plus, elles devaient démontrer un temps de circulation plasmatique prolongée afin de favoriser l’accumulation passive du médicament encapsulé au niveau de la tumeur. La première partie du travail visait à employer pour la première fois le copolymère amphiphile PVP-b-PDLLA comme émulsifiant dans la préparation de nanoparticules polymères. Ainsi, une méthode de fabrication des nanoparticules par émulsion huile-dans-eau a été appliquée afin de produire des nanoparticules à base de PDLLA de taille inférieure à 250 nm. Grâce aux propriétés lyoprotectrices de la couronne de PVP présente à la surface des nanoparticules, celles-ci pouvaient retrouver leur distribution de taille initiale après lyophilisation et redispersion en milieu aqueux. Deux anticancéreux hydrophobes, soit le PTX et l’étoposide (ETO), ont été encapsulés dans les nanoparticules et libérés de ces dernières de façon contrôlée sur plusieurs jours in vitro. Une procédure de « salting-out » a été appliquée afin d’améliorer le taux d’incorporation de l’ETO initialement faible étant donnée sa solubilité aqueuse légèrement supérieure à celle du PTX. Le second volet des travaux visait à comparer le PVP comme polymère de surface des nanoparticules au PEG, le polymère le plus fréquemment employé à cette fin en vectorisation. Par le biais d’études d’adsorption de protéines, de capture par les macrophages et de biodistribution chez le rat, nous avons établi une corrélation in vitro/in vivo démontrant que le PVP n’était pas un agent de surface aussi efficace que le PEG. Ainsi, malgré la présence du PVP à la surface des nanoparticules de PDLLA, ces dernières étaient rapidement éliminées de la circulation sanguine suite à leur capture par le système des phagocytes mononucléés. Par conséquent, dans le troisième volet de cette thèse, le PEG a été retenu comme agent de surface, tandis que différents polymères biodégradables de la famille des polyesters, certains synthétiques (PDLLA et copolymères d’acide lactique/acide glycolique), d’autres de source naturelle (poly(hydroxyalkanoates)(PHAs)), ont été investiguées comme matériaux formant le cœur des nanoparticules. Il en est ressorti que les propriétés physicochimiques des polyesters avaient un impact majeur sur l’efficacité d’encapsulation du PTX et son profil de libération des nanoparticules in vitro. Contrairement aux PHAs, les polymères synthétiques ont démontré des taux d’incorporation élevés ainsi qu’une libération contrôlée de leur cargo. Des études de pharmacocinétique et de biodistribution ont démontré que les nanoparticules de PDLLA dotées d’une couronne de PEG conféraient un temps de circulation plasmatique prolongé au PTX et favorisaient son accumulation tumorale. Les nanoparticules polymères représentent donc une alternative intéressante au Taxol®. / Many highly potent anticancer drugs are characterized by poor aqueous solubility and can impart significant systemic toxicity. This toxicity can be attributed in part to the solubilisation of these anticancer agents with low molecular weight surfactants that are known to cause serious biological side effects on their own. Moreover, following their intravenous (IV) injection, the anticancer agents distribute throughout the body, causing deleterious effects in healthy organs and tissues. Colloidal polymeric drug carriers have been investigated as a means to circumvent these drawbacks. First, polymeric materials can be tailored to meet specific requirements in terms of biocompatibility, biodegradability and affinity for the cargo molecule. Second, associating a drug to a carrier system can drastically alter its distribution throughout the body, enhancing its deposition at the target site, e.g. the tumour, while sparing healthy tissues, thus minimizing systemic toxicity. Previous work in our group has led to the design of block copolymer micelles based on poly(N-vinyl-pyrrolidone)-block-poly(D,L-lactide) (PVP-b-PDLLA) that were shown to solubilise hydrophobic anticancer agents such as paclitaxel (PTX). PTX is commercially available as Taxol®, a Cremophor EL (CrEL)-based formulation. CrEL is a low molecular weight surfactant that has been linked to severe side effects including life-threatening hypersensitivity reactions. Although PTX-loaded PVP-b-PDLLA micelles have demonstrated much improved tolerability compared to Taxol®, they did not increase PTX tumoral concentrations and exhibited anticancer efficacy similar to Taxol® at equivalent dosage. This was attributed to rapid destabilisation of the micelles and release of their cargo following IV administration. We chose to pursue our work with a colloidal drug carrier that exhibits greater stability compared to block copolymer micelles, i.e. polymeric nanoparticles. The main objective of this project was to develop polymeric nanoparticles for the parenteral delivery of hydrophobic anticancer drugs. The nanoparticles had to meet certain requirements such as be able to encapsulate hydrophobic anticancer drugs and release them in a controlled fashion over several days. Furthermore, the nanoparticles should confer prolonged plasma residence times to the encapsulated drug and favour its passive accumulation at its intended site of action, i.e. the tumour. The first part of this work focussed on applying PVP-b-PDLLA for the first time as polymeric emulsifier for the preparation of PDLLA nanoparticles with appropriate mean diameters (250 nm) using an oil-in-water emulsion method. Two hydrophobic anticancer drugs, PTX and etoposide (ETO), were successfully incorporated into the nanoparticles. A salting-out method was applied to enhance the loading efficiency of ETO, which was initially low given its slightly higher aqueous solubility compared to PTX. Both drugs were released in a controlled fashion from the PDLLA nanoparticles in vitro. Because of the lyoprotective effect of PVP, the polymer corona allowed for the particles to be easily redispersed in aqueous media following lyophilisation. The second part of the thesis aimed at evaluating whether the PVP coating could confer “stealth” properties to the PDLLA nanoparticles. Our study provided direct comparison between PVP and PEG, the most widely employed surface agent in drug delivery. In vitro protein adsorption and phagocytosis studies corroborated the in vivo findings, which showed that PVP-coated nanoparticles were rapidly cleared from circulation following their uptake by the mononuclear phagocyte system. Hence, our results indicated that PVP as coating materiel is not as efficient as PEG in conferring “stealth” properties to polymeric nanoparticles. Consequently, in the last section of this thesis, PEG was selected as coating agent while various biodegradable polymers were investigated as core-forming materials. Both synthetic (PDLLA and lactide/glycolide copolymers) and natural (polyhydroxyalkanoates (PHAs)) polyesters were tested. Our results demonstrated that the physicochemical properties of the polyesters significantly influenced the loading efficiency and release kinetics of PTX. While nanoparticles based on synthetic polyesters exhibited high encapsulation levels and controlled PTX release in vitro, PHA-based nanoparticles exhibited immediate unloading of their cargo. Pharmacokinetic and biodistribution studies in rodents revealed that encapsulating PTX in PEG-coated PDLLA-based nanoparticles led to enhanced plasma residence time and tumour deposition of the drug compared to Taxol®. Polymeric nanoparticles thus represent an appealing alternative to Taxol®.